Global Clinical Trials announces the first successful screening in the endometriosis study.
It is a Phase III double-blind, three-arm superiority study in 200+ subjects that is being conducted in Ukraine. The study aims to assess the safety and efficacy of the Investigational Product (IP) for treatment of endometriosis in women of reproductive age.
GCThas been running Women’s Health clinical trials since 2001, and it is one of GCT’s main–focus therapeutic areas. GCT is well–familiar with Key Opinion Leaders (KOLs) and clinical sites, and utilizes this expertise to ensure an effective enrollment of patients for its projects.
“GCT is proud to achieve this milestone in such a short time. Together, GCT, sites, and the Sponsor’s team engaged all their efforts to make it happen, “ said Dr. Eugene Selivra, GCT CEO.
Endometriosis is an incurable but manageable gynecological condition. It occurs when endometrial implants, comprised of tissue normally found within the uterus, are present in other areas of the body. It is a long-term condition that can have a significant impact on the life of the patient.
To plan a new endometriosis clinical trial with GCT, please contact us at bd@gctrials.com.